Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Increasing evidence indicates an important role of transcription factor Yin Yang-1 (YY1) in human tumorigenesis. However, its function in cancer remains controversial and the relevance of YY1 to pancreatic ductal adenocarcinoma (PDAC) remains to be clarified.

Methods

In this study, we detected YY1 expression in clinical PDAC tissue samples and cell lines using quantitative RT-PCR, immunohistochemistry and western blotting. We also detected MUC4 and MMP10 mRNA levels in 108 PDAC samples using qRT-PCR and analyzed the correlations between YY1 and MUC4 or MMP10 expression. The role of YY1 in the proliferation, invasion and metastatic abilities of PDAC cells in vitro was studied by CCK-8 assay, cell migration and invasion assays. In vivo pancreatic tumor growth and metastasis was studied by a xenogenous subcutaneously implant model and a tail vein metastasis model. The potential mechanisms underlying YY1 mediated tumor progression in PDAC were explored by digital gene expression (DGE) sequencing, signal transduction pathways blockage experiments and luciferase assays. Statistical analysis was performed using the SPSS 15.0 software.

Results

We found that the expression of YY1 in PDACs was higher compared with their adjacent non-tumorous tissues and normal pancreas tissues. However, PDAC patients with high level overexpression of YY1 had better outcome than those with low level overexpression. YY1 expression levels were statistically negatively correlated with MMP10 expression levels, but not correlated with MUC4 expression levels. YY1 overexpression suppressed, whereas YY1 knockdown enhanced, the proliferation, invasion and metastatic properties of BXPC-3 cells, both in vitro and in vivo. YY1 suppresses invasion and metastasis of pancreatic cancer cells by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.

Conclusions

The present study suggested that YY1 plays a negative role, i.e. is a tumor suppressor, in PDAC, and may become a valuable diagnostic and prognostic marker of PDAC.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
3.
Shi Y, Seto E, Chang LS, Shenk T: Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 1991, 67: 377-388. 10.1016/0092-8674(91)90189-6.CrossRefPubMed
4.
Shi Y, Lee JS, Galvin KM: Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta. 1997, 1332: F49-F66.PubMed
5.
Gordon S, Akopyan G, Garban H, Bonavida B: Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006, 25: 1125-1142. 10.1038/sj.onc.1209080.CrossRefPubMed
6.
7.
Thomas MJ, Seto E: Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key?. Gene. 1999, 236: 197-208. 10.1016/S0378-1119(99)00261-9.CrossRefPubMed
8.
Hyde-DeRuyscher RP, Jennings E, Shenk T: DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res. 1995, 23: 4457-4465. 10.1093/nar/23.21.4457.PubMedCentralCrossRefPubMed
9.
Usheva A, Shenk T: TATA-binding protein-independent initiation: YY1, TFIIB, and RNA polymerase II direct basal transcription on supercoiled template DNA. Cell. 1994, 76: 1115-1121. 10.1016/0092-8674(94)90387-5.CrossRefPubMed
10.
Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B: Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005, 27: 131-141.PubMed
11.
Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee PS, Murphy SK, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005, 11: 3686-3704. 10.1158/1078-0432.CCR-04-2398.CrossRefPubMed
12.
Chinnappan D, Xiao D, Ratnasari A, Andry C, King TC, Weber HC: Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol. 2009, 34: 1417-1423.PubMed
13.
Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V, Vinkler R, Boniver J, Delvenne P, Begon DY: The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res. 2008, 10: R9-10.1186/bcr1851.PubMedCentralCrossRefPubMed
14.
de Nigris F, Botti C, de Chiara A, Rossiello R, Apice G, Fazioli F, Fiorito C, Sica V, Napoli C: Expression of transcription factor Yin Yang 1 in human osteosarcomas. Eur J Cancer. 2006, 42: 2420-2424. 10.1016/j.ejca.2006.06.008.CrossRefPubMed
15.
Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R: Identification and validation of commonly overexpresssed genes in solid tumors by comparison of microarray data. Neoplasia. 2004, 6: 744-750. 10.1593/neo.04277.PubMedCentralCrossRefPubMed
16.
Zaravinos A, Spandidos DA: Yin yang 1 expression in human tumors. Cell Cycle. 2010, 9: 512-522. 10.4161/cc.9.3.10588.CrossRefPubMed
17.
He G, Wang Q, Zhou Y, Wu X, Wang L, Duru N, Kong X, Zhang P, Wan B, Sui L, Guo Q, Li JJ, Yu L: YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide. Int J Gynecol Cancer. 2011, 21: 1097-1104. 10.1097/IGC.0b013e31821d2525.PubMedCentralCrossRefPubMed
18.
Sakhinia E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, Radford JA, Byers RJ: Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood. 2007, 109: 3922-3928. 10.1182/blood-2006-09-046391.CrossRefPubMed
19.
Castellano G, Torrisi E, Ligresti G, Nicoletti F, Malaponte G, Travali S, McCubrey JA, Canevari S, Libra M: Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle. 2010, 9: 557-563. 10.4161/cc.9.3.10554.CrossRefPubMed
20.
de Nigris F, Rossiello R, Schiano C, Arra C, Williams-Ignarro S, Barbieri A, Lanza A, Balestrieri A, Giuliano MT, Ignarro LJ, Napoli C: Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res. 2008, 68: 1797-1808. 10.1158/0008-5472.CAN-07-5582.CrossRefPubMed
21.
Naidoo K, Clay V, Hoyland JA, Swindell R, Linton K, Illidge T, Radford JA, Beyers RJ: YY1 expression predicts favourable outcome in follicular lymphoma. J Clin Pathol. 2011, 64: 125-129. 10.1136/jcp.2010.078188.CrossRefPubMed
22.
Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES: Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem. 2012, 287: 15935-15946. 10.1074/jbc.M112.341156.PubMedCentralCrossRefPubMed
23.
Zhang JJ, Zhu Y, Zhang XF, Liang WB, Xie KL, Tao JQ, Peng YP, Xu ZK, Miao Y: Transcriptional regulation of human MUC4 gene: identification of a novel inhibitory element and its nuclear binding protein. Mol Biol Rep. 2013, 40: 4913-4920. 10.1007/s11033-013-2591-6.CrossRefPubMed
24.
Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK: MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 2008, 68: 2065-2070. 10.1158/0008-5472.CAN-07-6041.PubMedCentralCrossRefPubMed
25.
Jonckheere N, Skrypek N, Merlin J, Dessein AF, Dumont P, Leteurtre E, Harris A, Desseyn JL, Susini C, Frénois F, Van Seuningen I: The mucin MUC4 and Its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS One. 2012, 7: e32232-10.1371/journal.pone.0032232.PubMedCentralCrossRefPubMed
26.
Momi N, Ponnusamy MP, Kaur S, Rachagani S, Kunigal SS, Chellappan S, Ouellette MM, Batra SK: Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through α7nAChR-mediated MUC4 upregulation. Oncogene. 2013, 32: 1384-1395. 10.1038/onc.2012.163.PubMedCentralCrossRefPubMed
27.
Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN: Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006, 126: 321-334. 10.1016/j.cell.2006.05.040.CrossRefPubMed
28.
Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ: Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature. 1997, 386: 296-299. 10.1038/386296a0.CrossRefPubMed
29.
de Angelis L, Zhao J, Andreucci JJ, Olson EN, Cossu G, McDermott JC: Regulation of vertebrate myotome development by the p38 MAP kinase-MEF2 signaling pathway. Dev Biol. 2005, 283: 171-179. 10.1016/j.ydbio.2005.04.009.CrossRefPubMed
30.
31.
de Nigris F, Crudele V, Giovane A, Casamassimi A, Giordano A, Garban HJ, Cacciatore F, Pentimalli F, Marquez-Garban DC, Petrillo A, Cito L, Sommese L, Fiore A, Petrillo M, Siani A, Barbieri A, Arra C, Rengo F, Hayashi T, Al-Omran M, Ignarro LJ, Napoli C: CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci U S A. 2010, 107: 14484-14489. 10.1073/pnas.1008256107.PubMedCentralCrossRefPubMed
32.
Sui G, Affar el B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR, Shi Y: Yin Yang 1 is a negative regulator of p53. Cell. 2004, 117: 859-872. 10.1016/j.cell.2004.06.004.CrossRefPubMed
33.
Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, Liu TH, Bian XW, Guan XY, Lin MC, Zeng MS, Zeng YX, Kung HF, Xie D: EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a corepressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 2012, 31: 583-594.PubMed
34.
Wang CC, Tsai MF, Hong TM, Chang GC, Chen CY, Yang WM, Chen JJ, Yang PC: The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene. 2005, 24: 4081-4093. 10.1038/sj.onc.1208573.CrossRefPubMed
35.
Lee MH, Lahusen T, Wang RH, Xiao C, Xu X, Hwang YS, He WW, Shi Y, Deng CX: Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation. Oncogene. 2012, 31: 116-127. 10.1038/onc.2011.217.CrossRefPubMed
36.
Austen M, Cerni C, Luscher-Firzlaff JM, Luscher B: YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc. Oncogene. 1998, 17: 511-520. 10.1038/sj.onc.1201968.CrossRefPubMed
37.
Jonckheere N, Skrypek N, van Seuningen I: Mucins and pancreatic cancer. Cancers (basel). 2010, 2: 1794-1812. 10.3390/cancers2041794.CrossRef
38.
Komoto M, Nakata B, Amano R, Yamada N, Yashiro M, Ohira M, Wakasa K, Hirakawa K: HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci. 2009, 100: 1243-1247. 10.1111/j.1349-7006.2009.01176.x.CrossRefPubMed
39.
Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25: 9-34. 10.1007/s10555-006-7886-9.CrossRefPubMed
40.
Gill JH, Kirwan IG, Seargent JM, Martin SW, Tijani S, Anikin VA, Mearns AJ, Bibby MC, Anthoney A, Loadman PM: MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia. 2004, 6: 777-785. 10.1593/neo.04283.PubMedCentralCrossRefPubMed
41.
McKinsey TA, Zhang CL, Olson EN: MEF2: A calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002, 27: 40-47. 10.1016/S0968-0004(01)02031-X.CrossRefPubMed
42.
Kloppel G, Hruban RH, Longnecker DS: Ductal adenocarcinoma of the pancreas. WHO Classification of Tumors: Pathology and Genetics of Tumors of the Digestive System. Edited by: Hamilton SR, Aaltonen LA. 2000, Lyon: IARC Press, 221-230.
43.
Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS: Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007, 110: 738-744. 10.1002/cncr.22852.CrossRefPubMed
44.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using realtime quantitative PCR and the 2-ΔΔCT method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
45.
Stovall DB, Wan M, Zhang Q, Dubey P, Sui G: DNA vector-based RNA interference to study gene function in cancer. J Vis Exp. 2012, 64: e4129-PubMed
46.
’t Hoen PA, Ariyurek Y, Thygesen HH, Vreugdenhil E, Vossen RH, De-Menezes RX, Boer JM, Van-Ommen GJ, Den-Dunnen JT: Deep sequencing-based expression analysis shows major advances in robustness, resolution and inter-lab portability over five microarray platforms. Nucleic Acids Res. 2008, 36: e141-10.1093/nar/gkn705.PubMedCentralCrossRefPubMed
47.
Morrissy AS, Morin RD, Delaney A, Zeng T, McDonald H, Jones S, Zhao Y, Hirst M, Marra MA: Next-generation tag sequencing for cancer gene expression profiling. Genome Res. 2009, 19: 1825-1835. 10.1101/gr.094482.109.PubMedCentralCrossRefPubMed
48.
Audic S, Claverie JM: The significance of digital gene expression profiles. Genome Res. 1997, 7: 986-995.PubMed
49.
Benjamini Y, Yekutieli D: The control of the false discovery rate in multiple testing under dependency. Ann Statist. 2001, 29: 1165-1188. 10.1214/aos/1013699998.CrossRef
50.
Hanley J: Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imagin. 1989, 29: 307-335.
51.
Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 2004, 350: 379-392. 10.1056/NEJMra035536.CrossRefPubMed
52.
Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A: Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007, 60: 1112-1116. 10.1136/jcp.2006.044537.PubMedCentralCrossRefPubMed
Metadata
Title
Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism
Publication date
01-12-2014
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-130

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells

Research

The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy

Research

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

Research

Hepatitis B virus X protein specially regulates the sialyl lewis a synthesis among glycosylation events for metastasis

Research

Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer

Research

Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits